Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCNBC· September 30, 2026

Kalshi, Polymarket trading volumes on some products raises questions amid massive growth

View original at cnbc.com
Kalshi, Polymarket trading volumes on some products raises questions amid massive growth Trading volumes for certain products on prediction market platforms Kalshi and Polymarket are raising questions from some industry observers, who fear the numbers may be inflated…
Opening lines of the source · CNBC · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Polymarket denies wash trading occurs on any of its products and says the low-odds contract patterns are not inorganic.

    60% confidence
  • Low-odds contract popularity on Polymarket is driven by sharps correcting mispricings, which is healthy for markets.

    60% confidence
  • Low-odds contract activity is more common on Polymarket's international exchange because it has more sharps, while the U.S. exchange is dominated by casual retail traders.

    60% confidence
  • The CFTC has a zero tolerance policy on manipulative trading, including wash trading, insider trading and fraud.

    60% confidence
  • Wash-trading-like patterns fell to a negligible amount by April 2026, but the lingering popularity of low-odds contracts is concerning.

    60% confidence
  • Kalshi's liquidity looks provided to harvest incentives, creating the appearance of liquidity.

    60% confidence
  • Kalshi's perpetual volume does not look organic.

    60% confidence
  • A designated contract market has a duty to monitor market conditions, price movements and volumes in real time for abnormalities.

    60% confidence
  • Kalshi has zero concerns about the ratio of volume to resting liquidity.

    60% confidence
  • Kalshi's fee rebates let aggressive liquidity takers profit consistently from arbitrage, and he disagrees that this is fine, though he does not attribute it to wash trading.

    60% confidence
  • The Ethiopian PM contract will resolve when the government elected this summer is officially sworn in, slated for Oct. 5.

    60% confidence
  • Kalshi denies any wash trading occurs on its platform and says it tracked hundreds of users involved in the flagged trades.

    60% confidence
  • If a material share of reported perpetual volume is manufactured, headline volume may overstate underlying trading demand, which matters most for retail investors at a public listing.

    60% confidence
  • Expanded surveillance and the introduction of fees have weakened chances for market manipulation on Polymarket.

    60% confidence
  • Token airdrops reward early users who help a platform scale, and eligibility may be based on open interest or individual volumes.

    60% confidence
  • Differences in volume come partly from Kalshi's lower leverage, its ban on requoting by market makers, and U.S. rules against incentivizing users to park capital. Comparing Kalshi to offshore exchanges is apples and oranges.

    60% confidence
  • The Polymarket contracts on very long shots look like someone putting up low-risk volume.

    60% confidence
  • Kalshi's ether perpetual trades amounted to wash trading.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com